L. Becker  Hewes net worth and biography

L. Hewes Biography and Net Worth

Becker brings 20 years of industry and clinical experience in oncology and hematology, including achieving the approval of three tyrosine kinase inhibitors. Previously, he served as Blueprint Medicines’ Senior Vice President, Clinical Development from May 2020 to January 2021. Prior to joining Blueprint Medicines, Becker served as Chief Medical Officer of Repertoire Immune Medicines (formerly Torque Therapeutics) from February 2017 to May 2020, where he built Repertoire’s multidisciplinary clinical and biomarker team and advanced its lead immuno-oncology programs into clinical development. From June 2013 to February 2017, Becker served as Executive Director of Translational Clinical Oncology at the Novartis Institutes for BioMedical Research where he led clinical development and translational medicine efforts for multiple early-stage oncology programs through clinical proof-of-concept, including Kisqali® (ribociclib), a targeted therapy approved to treat breast cancer, and other programs combining novel therapies. Prior to that, he held roles of increasing responsibility related to clinical development in oncology and hematology within AstraZeneca PLC, Genzyme Corporation and Wyeth Pharmaceuticals, including leading registration programs for Bosulif® (bosutinib) and Torisel® (temsirolimus) for chronic myelogenous leukemia and mantle cell lymphoma, respectively. Before joining industry, he conducted immuno-oncology research at the Emory Vaccine Center while treating patients as a pediatric oncologist at Children’s Healthcare of Atlanta. Becker holds an M.D. from the Georgetown University School of Medicine and a B.S. from Vanderbilt University.

How do I contact L. Becker Hewes?

The corporate mailing address for Mr. Hewes and other Blueprint Medicines executives is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. Blueprint Medicines can also be reached via phone at (617) 374-7580 and via email at [email protected]. Learn More on L. Becker Hewes' contact information.

Has L. Becker Hewes been buying or selling shares of Blueprint Medicines?

L. Becker Hewes has not been actively trading shares of Blueprint Medicines during the past quarter. Learn More on L. Becker Hewes' trading history.

Who are Blueprint Medicines' active insiders?

Blueprint Medicines' insider roster includes Jeffrey Albers (CEO), Percy Carter (Insider), George Demetri (Director), Debra Durso-Bumpus (Insider), Mark Goldberg (Director), Kate Haviland (COO), L. Hewes (Insider), Ariel Hurley (Insider), Michael Landsittel (CFO), Nicholas Lydon (Director), Tracey Mccain (EVP), Christopher Murray (Insider), Fouad Namouni (Insider), Christina Rossi (Insider), and Charles Rowland, Jr. (Director). Learn More on Blueprint Medicines' active insiders.

Are insiders buying or selling shares of Blueprint Medicines?

In the last twelve months, insiders at the biotechnology company sold shares 23 times. They sold a total of 167,543 shares worth more than $13,239,414.59. The most recent insider tranaction occured on March, 20th when Director Jeffrey W Albers sold 25,073 shares worth more than $2,188,371.44. Insiders at Blueprint Medicines own 3.9% of the company. Learn More about insider trades at Blueprint Medicines.

Information on this page was last updated on 3/20/2024.

L. Becker Hewes Insider Trading History at Blueprint Medicines

See Full Table

L. Becker Hewes Buying and Selling Activity at Blueprint Medicines

This chart shows L. Becker Hewes's buying and selling at Blueprint Medicines by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Blueprint Medicines Company Overview

Blueprint Medicines logo
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $94.86
Low: $93.50
High: $95.98

50 Day Range

MA: $86.36
Low: $73.17
High: $99.79

2 Week Range

Now: $94.86
Low: $41.54
High: $101.00

Volume

646,740 shs

Average Volume

811,327 shs

Market Capitalization

$5.81 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63